Tokyo Tape
Sign in
← Nihon Chouzai

Quarterly report · Q2

3341.TEDINET S100PM0M
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥152.3bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥299.4bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥146.2bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥2.8bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥2.4bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥2.8bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥6.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.5bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥2.9bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥2.4bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥1.6bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥3.7bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.3bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥1.6bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥1.3bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥187.6bnat 2022-09-30Cons.Assets
Total assets¥178.8bnat 2022-03-31Cons.Assets
Total assets¥184.4bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥133.6bnat 2022-09-30Cons.Liabilities
Total liabilities¥125.9bnat 2022-03-31Cons.Liabilities
Net assets / equity¥54.0bnat 2022-09-30Cons.Net assets
Net assets / equity¥52.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥50.8bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥21.5bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥25.5bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥21.5bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥25.5bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥27.8bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥32.9bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥1.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥19.4bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥10.7bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥7.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥9.3bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥5.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥2.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥17.4bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥10.9bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥53.662022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥40.622022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥123.562021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥44.712021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥30.442021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio28.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio29.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio27.6%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 37
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥7.0bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥7.0bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥3.3bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥136.2bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥136.2bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1m
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥6.0bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥4.0bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥4.0bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥9m
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥500m
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥19.2bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥12.2bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥7.0bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥396m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥159.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥152.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥7.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥6.1bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥9.9bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥9.9bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥3.3bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥128.7bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥128.7bn
jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥5.0bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥3.6bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥3.6bn
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥5m
jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥440m
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥23.7bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥13.8bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥9.9bn
jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥195m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥156.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥146.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥9.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥5.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 515
ItemContextValueUnit
Insurance income noiPrior1YTDDuration132000000JPY
Insurance income noiCurrentYTDDuration51000000JPY
Subsidy income noiPrior1YTDDuration30000000JPY
Subsidy income noiCurrentYTDDuration21000000JPY
Other noiPrior1YTDDuration204000000JPY
Other noiCurrentYTDDuration161000000JPY
Non operating incomePrior1YTDDuration634000000JPY
Non operating incomeCurrentYTDDuration544000000JPY
Interest expenses noePrior1YTDDuration156000000JPY
Interest expenses noeCurrentYTDDuration133000000JPY
Rent expense noePrior1YTDDuration188000000JPY
Rent expense noeCurrentYTDDuration218000000JPY
Other noePrior1YTDDuration176000000JPY
Other noeCurrentYTDDuration156000000JPY
Non operating expensesPrior1YTDDuration522000000JPY
Non operating expensesCurrentYTDDuration508000000JPY
Ordinary incomePrior1YTDDuration2528000000JPY
Ordinary incomeCurrentYTDDuration2849000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration5000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration47000000JPY
Compensation income eiPrior1YTDDuration－JPY
Compensation income eiCurrentYTDDuration120000000JPY
Reversal of provision for directors retirement benefits eiPrior1YTDDuration46000000JPY
Reversal of provision for directors retirement benefits eiCurrentYTDDuration－JPY
Extraordinary incomePrior1YTDDuration52000000JPY
Extraordinary incomeCurrentYTDDuration167000000JPY
Impairment loss elPrior1YTDDuration228000000JPY
Impairment loss elCurrentYTDDuration114000000JPY
Loss on sales of noncurrent assets elPrior1YTDDuration－JPY
Loss on sales of noncurrent assets elCurrentYTDDuration51000000JPY
Extraordinary lossPrior1YTDDuration228000000JPY
Extraordinary lossCurrentYTDDuration166000000JPY
Income before income taxesPrior1YTDDuration2352000000JPY
Income before income taxesCurrentYTDDuration2850000000JPY
Income taxes currentPrior1YTDDuration1422000000JPY
Income taxes currentCurrentYTDDuration1094000000JPY
Income taxes deferredPrior1YTDDuration-409000000JPY
Income taxes deferredCurrentYTDDuration148000000JPY
Income taxesPrior1YTDDuration1012000000JPY
Income taxesCurrentYTDDuration1243000000JPY
Profit lossPrior1YTDDuration1340000000JPY
Profit lossCurrentYTDDuration1607000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration1340000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration1607000000JPY
Profit lossPrior1YTDDuration1340000000JPY
Profit lossCurrentYTDDuration1607000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration10000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration7000000JPY
Other comprehensive incomePrior1YTDDuration10000000JPY
Other comprehensive incomeCurrentYTDDuration7000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass